Who makes PEA-LUT 1 sachet?

PEA-LUT 1 sachet is developed by University Of Perugia.

What development phase is PEA-LUT 1 sachet in?

PEA-LUT 1 sachet is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

PEA-LUT 1 sachet

University Of Perugia · FDA-approved active Small molecule Quality 0/100

PEA-LUT, a sachet formulation developed by the University of Perugia, is currently marketed but lacks detailed revenue data. The drug's key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. Without specific trial results or primary indication details, the primary risk remains the uncertainty around its therapeutic efficacy and market differentiation.

At a glance

Generic name	PEA-LUT 1 sachet
Sponsor	University Of Perugia
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Tinnitus and Treatment With umPEA-LUT (NA)
Olfactory Disfunction and Co-ultraPEALut (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PEA-LUT 1 sachet CI brief — competitive landscape report
PEA-LUT 1 sachet updates RSS · CI watch RSS
University Of Perugia portfolio CI